Dmytro Kharkov

Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk

Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk
@phathompharma: GLP-1 linked to higher GERD risk

Phathom Pharmaceuticals has unveiled new research findings indicating that the use of GLP-1s in individuals with Type 2 Diabetes is associated with higher rates of gastroesophageal reflux disease (GERD) and related complications, compared to the use of SGLT-2 inhibitors.

This study is being highlighted during GERD Awareness Week to deepen the understanding of GERD and its implications on health. The data stems from real-world observations and promises to contribute significantly to the medical community's appreciation of the nuanced effects of diabetes medications on digestive health.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.